Analyst Ratings For Acer Therapeutics Inc (NASDAQ:ACER)
Today, HC Wainwright reiterated its Buy rating on Acer Therapeutics Inc (NASDAQ:ACER) with a price target of $10.00.
There are 3 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Acer Therapeutics Inc (NASDAQ:ACER) is Hold with a consensus target price of $31.00 per share, a potential 725.59% upside.
Some recent analyst ratings include
- 6/26/2019-Acer Therapeutics Inc (NASDAQ:ACER) had its Buy ➝ Buy rating reiterated by HC Wainwright with a $10.00 price target
- 6/25/2019-Acer Therapeutics Inc (NASDAQ:ACER) gets downgraded to Market Perform by Raymond James
- 6/25/2019-Acer Therapeutics Inc (NASDAQ:ACER) gets downgraded to Hold by Needham & Company LLC
- 6/25/2019-Acer Therapeutics Inc (NASDAQ:ACER) gets downgraded to Market Perform by William Blair
About Acer Therapeutics Inc (NASDAQ:ACER)
Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. Read More…
Recent Trading Activity for Acer Therapeutics Inc (NASDAQ:ACER)
Shares of Acer Therapeutics Inc closed the previous trading session at 3.75 −0.37 8.86% with 4.06 shares trading hands.